An individualized protein-based prognostic model to stratify pediatric patients with papillary thyroid carcinoma.

Journal: Nature communications
Published Date:

Abstract

Pediatric papillary thyroid carcinomas (PPTCs) exhibit high inter-tumor heterogeneity and currently lack widely adopted recurrence risk stratification criteria. Hence, we propose a machine learning-based objective method to individually predict their recurrence risk. We retrospectively collect and evaluate the clinical factors and proteomes of 83 pediatric benign (PB), 85 pediatric malignant (PM) and 66 adult malignant (AM) nodules, and quantify 10,426 proteins by mass spectrometry. We find 243 and 121 significantly dysregulated proteins from PM vs. PB and PM vs. AM, respectively. Function and pathway analyses show the enhanced activation of the inflammatory and immune system in PM patients compared with the others. Nineteen proteins are selected to predict recurrence using a machine learning model with an accuracy of 88.24%. Our study generates a protein-based personalized prognostic prediction model that can stratify PPTC patients into high- or low-recurrence risk groups, providing a reference for clinical decision-making and individualized treatment.

Authors

  • Zhihong Wang
    Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • He Wang
    Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, China International Neuroscience Institute, Beijing, China.
  • Yan Zhou
    Department of Computer Science, University of Texas at Dallas, Richardson, Texas 75080, United States.
  • Lu Li
    State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, China.
  • Mengge Lyu
    School of Medicine, School of Life Sciences, Westlake University, Hangzhou, China.
  • Chunlong Wu
    Westlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou, China.
  • Tianen He
    School of Medicine, School of Life Sciences, Westlake University, Hangzhou, China.
  • Lingling Tan
    Westlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou, China.
  • Yi Zhu
    2State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong China.
  • Tiannan Guo
    Institute of Basic Medical Sciences, School of Life Science, Westlake University, Hangzhou 310024, China.
  • Hongkun Wu
    Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wuhongkun@zju.edu.cn.
  • Hao Zhang
    College of Mechanical and Electrical Engineering, Henan Agricultural University, Zhengzhou, 450002, China.
  • Yaoting Sun
    School of Medicine, School of Life Sciences, Westlake University, Hangzhou, China. sunyaoting@westlake.edu.cn.